IP Library Granted Patent US 7,901,711
Granted Patent B1
US 7,901,711 · App. 11/974,836 · Granted Mar 8, 2011

Nanoparticles for protein/peptide delivery and delivery means thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,901,711
App. No.
11/974,836
Granted
Mar 8, 2011
Kind
B1
Abstract

The invention discloses the biodegradable nanoparticle for use in nanoparticle projectile bombardment as a carrier for administering proteins, peptides or siRNAs transdermally to an animal subject. The nanoparticles are composed of positively charged chitosan substrate, negatively charged core substrate complexed with chitosan, and encapsulated bioactive agents.

Claims (15)

1. A pharmaceutical composition of nanoparticles for transdermally lodging said nanoparticles in a target tissue of an animal subject, each nanoparticle comprising: a first component of a positively charged chitosan, a second component of a negatively charged substrate that complexes with said first component, wherein the second component is selected from the group consisting of PGA, α-PGA, soluble salts of PGA, metal salts of PGA and heparin, and at least one bioactive agent encapsulated within said nanoparticles, the at least one bioactive agent comprising a nucleic acid, wherein said first component dominates on a surface of said nanoparticles and the nanoparticles are about 50 μm to 500 μm in size.

2. The pharmaceutical composition according to claim 1 , wherein the nanoparticles are biodegradable.

3. The pharmaceutical composition according to claim 1 , wherein the bioactive agent comprises a protein or a peptide.

4. The pharmaceutical composition according to claim 1 , wherein the bioactive agent comprises plasmid protein.

5. The pharmaceutical composition according to claim 1 , wherein the bioactive agent is a ribonucleic acid.

6. The pharmaceutical composition according to claim 1 , wherein the bioactive agent is a deoxyribonucleic acid.

7. The pharmaceutical composition according to claim 1 , wherein the bioactive agent is a small interfering ribonucleic acid.

8. The pharmaceutical composition according to claim 1 , wherein the bioactive agent comprises a growth factor.

9. The pharmaceutical composition according to claim 1 , wherein the nanoparticle is mixed with trehalose in a freeze-drying process, thus producing freeze-dried nanoparticle powder.

10. The pharmaceutical composition according to claim 1 , wherein the nanoparticle is mixed with hexan-1,2,3,4,5,6-hexyl in a freeze-drying process, thus producing freeze-dried nanoparticle powder.

11. The pharmaceutical composition according to claim 1 , wherein the nanoparticle is crosslinked.

12. The pharmaceutical composition according to claim 1 , wherein the nanoparticle further comprises an adenovirus vector, said adenovirus vector comprising a small interfering ribonucleic acid.

13. The pharmaceutical composition according to claim 1 , wherein the bioactive agent comprises hormone.

14. The pharmaceutical composition according to claim 1 , wherein the bioactive agent comprises insulin or insulin analog.

15. The pharmaceutical composition according to claim 1 , wherein the bioactive agent comprises an Alzheimer antagonist.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2016
From: GP MEDICAL, INC
To: NANOMEGA MEDICAL CORPORATION
Reel/Frame 038382/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2008
From: SUNG, HSING-WEN; LEE, PO-WEI; CHEN, MEI-CHIN; TU, HOSHENG
To: GP MEDICAL, INC.
Reel/Frame 020414/0924 →